CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs: 1 blog
twitter: 26 X users

patent: 4 patents

Citations

dimensions_citation: 192 Dimensions

Readers on

mendeley: 272 Mendeley

Summary Blogs X Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

NEW ANTI-MUC1 CARS AND GENE EDITED IMMUNE CELLS FOR SOLID TUMORS CANCER IMMUNOTHERAPY

Application WO-2022229412-A1

World Intellectual Property Organisation (WIPO)

EFFICIENT TCR GENE EDITING IN T LYMPHOCYTES

Application WO-2022204443-A1

World Intellectual Property Organisation (WIPO)

ENGINEERED T CELLS FOR EXPRESSION OF CHIMERIC ANITGEN RECEPTORS

Application WO-2022109498-A1

World Intellectual Property Organisation (WIPO)

T-CELLS EXPRESSING IMMUNE CELL ENGAGERS IN ALLOGENIC SETTINGS

Application WO-2022018262-A1

World Intellectual Property Organisation (WIPO)